ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia.

Abstract excerpt

Low curability of patients diagnosed with acute myeloid leukemia (AML) must be seen as a call for better understanding the disease's mechanisms and improving the treatment strategy. Therapeutic outcome of the crucial anthracycline-based induction therapy often can be compromised by a resistant phenotype associated with overexpression of ABCB1 transporters. Here, we evaluated clinical relevance of ABCB1 in a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anthracyclines
• Share to ATP Binding Cassette Transporter, Subfamily B